We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Module for Enhanced Mass Spectrometry Applications Combines Capillary Electrophoresis with Electron Spray Ionization

By LabMedica International staff writers
Posted on 27 Jun 2011
A new system for separation and characterization of proteins and other large molecules combines capillary electrophoresis (CE) with advanced electrospray ionization (ESI) into a single instrument designed for use with a mass spectrometer.

The new instrument is the Beckman Coulter, Inc. More...
(Brea CA, USA) CESI 8000 High-Performance Separation-ESI Module. The module incorporates Beckman's OptiMS technology and is the first commercial CESI sprayer combined with new capillary electrophoresis instrumentation specifically designed for mass spectrometry (MS).

OptiMS Technology integrates an intrinsically low flow CE separation with ESI in a single, dynamic process that takes place within a capillary. To achieve CESI, the distal end of the capillary is porous to ion flow, allowing the electrophoresis circuit to be bridged and ESI to be initiated within the same device.

The CESI-MS method is capable of generating separations of peptides with a high peak capacity, allowing the analysis of very complex samples at the proteome level. The ultra-low flow rates used by CE effectively reduce ion suppression and make it possible to detect post-translational modifications such as phosphorylation and sialylation, which typically hamper efficient ionization. High-separation efficiency and sensitivity permit the detection of peptides present in trace amounts. The selectivity of CE in front-end separation further enables the characterization of intact proteins, their isoforms, cleaved fragments, and complexes.

The CESI 8000 system also allows fast and efficient separations of drugs, drug metabolites, organic acids, amino acids, low molecular weight amines, peptides, nucleic acids, and nucleosides.

"The CESI 8000 was developed in collaboration with mass spectrometry researchers who work in a variety of applications and who sought to expand the range of analytes detected while improving overall assay sensitivity," said Jeff Chapman, director of Beckman Coulter Discovery Products. "The result is a front-end separation system that generates data complementary to HPLC (high pressure liquid chromatography) and provides scientists with important, previously unavailable information."

Related Links:

Beckman Coulter, Inc.




Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.